<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03033602</url>
  </required_header>
  <id_info>
    <org_study_id>W81WH-15-1-0391</org_study_id>
    <nct_id>NCT03033602</nct_id>
  </id_info>
  <brief_title>Brief Treatment for Posttraumatic Stress Disorder</brief_title>
  <official_title>Brief Treatment for PTSD: Enhancing Retention and Engagement</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston VA Research Institute, Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Texas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Boston VA Research Institute, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary goal of this study is to examine whether a brief treatment approach for PTSD is
      equally efficacious in the treatment of active duty service members relative to a first line
      treatment approach that requires much greater treatment dose.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goal of this randomized clinical trial is to investigate if a brief, written intervention
      for posttraumatic stress disorder (PTSD), Written Exposure Therapy (WET), is equally
      efficacious as an evidenced-based behavioral therapy, Cognitive Processing Therapy-Cognition
      only (CPT-C), in the treatment of PTSD in active duty military men and women with a diagnosis
      of PTSD who have deployed in support of a post-9/11. The primary study outcome will be change
      in symptom severity as assessed by the Clinician Administered PTSD Scale for Diagnostic and
      Statistical Manual-5 edition (CAPS-5). Independent assessors will evaluate participants using
      the CAPS-5 at baseline, 10- (post-treatment), 20-, and 30-week intervals after the start of
      treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 20, 2015</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinician Administered PTSD Scale, 5</measure>
    <time_frame>Change from baseline to 10-, 20-, 30-weeks post first treatment session</time_frame>
    <description>PTSD symptom scale</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>PTSD</condition>
  <arm_group>
    <arm_group_label>Written exposure therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 sessions of imaginal exposure therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CPT, cognitive only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>12 sessions of cognitive therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>written exposure therapy</intervention_name>
    <description>five sessions of writing about traumatic experience.</description>
    <arm_group_label>Written exposure therapy</arm_group_label>
    <other_name>WET</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>CPT, cognitive only</intervention_name>
    <description>12 sessions of cognitive therapy related to traumatic experience.</description>
    <arm_group_label>CPT, cognitive only</arm_group_label>
    <other_name>CPT-C</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female active duty military personnel who have deployed in support of a
             post-9/11 conflict seeking treatment for PTSD

          -  Diagnosis of PTSD

          -  Ability to speak, read and write English

          -  Not currently engaged in psychosocial treatment for PTSD

          -  Individuals taking psychotropic medications agree to work with their prescriber to
             remain on stable doses of any prescribed psychotropic medications for the duration of
             the intervention and through the first follow-up assessment as much as possible and as
             medically indicated.

        Exclusion Criteria:

          -  Current suicide or homicide risk meriting crisis intervention

          -  Active psychosis

          -  Moderate to severe brain damage
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Denise Sloan, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boston VA Research Institute, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alan Peterson, Ph.D.</last_name>
    <phone>(210) 562-6744</phone>
    <email>petersona3@uthscsa.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ft. Hood</name>
      <address>
        <city>Killeen</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Fowler, B.A.</last_name>
      <email>fowlerP@uthscsa.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center, San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Flores, BA</last_name>
      <email>floresa13@uthscsa.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 2, 2016</study_first_submitted>
  <study_first_submitted_qc>January 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2017</study_first_posted>
  <last_update_submitted>December 26, 2019</last_update_submitted>
  <last_update_submitted_qc>December 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

